RxDoctor Payments Data

Heather Strohm, APRN

Family · Laconia, NHNPI 1710517172

Payments from drug & device makers

$788in general payments, 2019–2025

Across 33 payments — averaging $23.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$441
  • AstraZeneca$126
  • AbbVie$108
  • Mylan Specialty L.p.$61
  • Verona Pharma, Inc.$31
  • Grifols USA, LLC$22

What the payments were for

  • Food & beverage$788100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$788 in reported general payments places this provider in the 80th percentile of 713 family providers in New Hampshire.

See all family providers in New Hampshire

Medicare billing

Part B allowed, 2024
$26,773
Medicare patients
128
Services billed
271

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter249$265,302
NucalaMepolizumab16$71,890
Breztri AerosphereBudesonide/Glycopyr/Formoterol69$56,288
Breo ElliptaFluticasone/Vilanterol39$27,197
Spiriva RespimatTiotropium Bromide16$19,600
SymbicortBudesonide/Formoterol Fumarate30$11,734
Incruse ElliptaUmeclidinium Bromide11$7,769
Stiolto RespimatTiotropium Br/Olodaterol Hcl13$6,388
Combivent RespimatIpratropium/Albuterol Sulfate12$6,242
Fluticasone-SalmeterolFluticasone Propion/Salmeterol45$5,797
Advair HfaFluticasone Propion/Salmeterol16$5,183
Albuterol Sulfate HfaAlbuterol Sulfate184$4,782
Fluticasone Propionate HfaFluticasone Propionate17$3,911
Pantoprazole Sodium255$3,331
Arnuity ElliptaFluticasone Furoate16$3,257

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta$441$375,416331 claims
AstraZenecaBreztri Aerosphere, Symbicort$126$68,02299 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 713 family providers in New Hampshire.

Other family in Laconia

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →